
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. demonstrated a robust financial performance in the second quarter of 2025, with revenue increasing by approximately 23% year-over-year to reach $46.4 million, reflecting strong demand for its innovative surgical implant products. Additionally, the company's gross margin improved by about 80 basis points compared to the previous year, attaining a level of 79.8%, which indicates efficient cost management and product profitability. Furthermore, an upward revision of the 2025 revenue estimate to $196.5 million, from a prior estimate of $193.9 million, underscores the company's positive trajectory driven by enhanced sales productivity and surgeon engagement.
Bears say
The financial outlook for SI-BONE Inc. is negatively affected by ongoing pricing pressures and procedural headwinds in the global spine market, leading to growth rates that have stagnated in the low-single digits. Additionally, competitive products may gain traction in the marketplace, potentially reducing SI-BONE's market share in sacroiliac joint fusion procedures, thereby negatively impacting revenue performance. Furthermore, SI-BONE's enterprise value-to-sales growth ratio of 0.19x falls significantly short of the median of 0.34x for its small to mid-cap growth peer group, indicating a relative undervaluation compared to its competitors.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares